The eHect of II novel immuoMUppressive agent, FK506, on fresh i.l~t allografts WIS evaluated In diabetic rats across major Ilistocompatlbility complex (MHC) barriers with respect to the transplantation (TR) site, Islet SOllrce, treatment regimen, and antidonor antibody (Ab) titen of the recipients after fR. The functional periods of Wistar (Wi) islets transplanted under kidney capsule IKe] or intraportally (IPo) and of a mixture of Wi and Lewis (I.e) islets under KC or IPo In nonimmunOluppressed ACI rat ",Ciplents were 6.9 :I: 0.4 In = 7),6.4;t: 0.5 In = 7), S.6 !t 0.4 In = 71, and 6.2 :t 0.4 In = Ii) days, respectively. FI<5OI treatment at 1 rng/kg/d intramu=>cularly 11M) for 2 weeks (protocol I) follOwing islet 1R under KC 
Assmment of Graft Function
Daily serum glucose levels and body weights of recipient rars were determined for 2 weakl after TR and then twice weekly thereafter. Rejection was coJlSidered to have oc:curred when the serum glucose IC'lCI ellCCCded 200 mgldL on 3 suQlCSSive days.
SuMliwi time for each recipient sroup i, ",ported as the mean == standard e11'Ol" of the mean. Statistical evaiuation was performed by the Mann-Whitney Utest. Apnlue of le55 than .OS was considered statistically significant.
An Intravenous glucose tolerance test (IVGTI). 1 ,/kg IV throup the femoral vein in ovcmlght..fasted animal&, was performed in some Islet recipients 1 weele after ehe last dole of PKS06.
Blood samples were collected from the tan at 0. 1 
Assessment of the EJflcacy 0{ FKS061mmunosuppression on Islet AllOflTtlft Survil'Qlln Sensitized RecipietllS
Diabetic ACI rats were transplanted with C",sh Wi islets under the left KC. After rejection or tile first islet allograft. a second Islet gra£1 frum the SlIme elonor lItrain was performed in the contraiateral kidney of the recipienL The second TR was performed either Il short or long perlud after the lint TR. The animals were treated with FKS06 os indicllted.
Antibody Studies
Collected sern were stored at -2O"C and heated at S6·C for 30 minutes before antibody (Ab) determination. Cytotoxic Ab levels in the ACI recipients of flab Wi b1cts with and wldlout ro06 treatment were dctcnnincd using pooled Wi strain splcnoc:ytcs lUI talget ceUs and rabbit serum as tile complement source (Low·Tox R complement. Ccdarlanc Laboratory. Hornby, Ontario, Canada).
Ab titer is defined as the reciprocal of serum dRuwa that IdIIs 50% of the target cells by trypan blue dye exclusion uuy.7
AuelSntem otTolera,,"
To U&eSS tbe possibility of toleranc:e in rats With lona·tcnn-functioning Wi islet allografts. under the KC (group 8 v 9). However, FlG06 efficacy was lower for mixed islet allogrdft than for islcts from a single donor strain in the KC but not IPo (group 6 v 8, P < .01; 7 v 9, NS).
Glucose metabulism was improved in AO rats with functioning Wi islctJ;. The glucose clearance (K) Tales of IVGTfs performed in ACI recipients with functional Wi islets undcr KC 1 week aftcr the last Injection of FK500 were 2.16 :t 0.09 (group 5, n = 6) and 1.83 :t 0.06 (group 6, Jl = 7), which were much improved over rates of the diabetic controls (K rate < 1.0) but significantly lower than those of nonnal control animals (K = 3.10 :t 0.11, n = 11).
To confinn that the long-term normalization of blood glucose levels in ACI ruts with Wi islets was not due to spontaneous reversion of diabetes. graft removal was performed in some animals. Nephrectomy of the graftcontaining kidnL'Y resulted in the return to hyperglyccmia in six out of six cases of ACI rats with Wi and two out of two with Wi + Lc isle\ allografts. Wi islet allograft with normal-appearing histology was observed under the KC 114 days after TR in diabelic ACl rats immunosuppres,'lCd with . protocol II. Insulin-comalning i:;letll were abundant. In some areas of the gnlft, small numhefll of CD4-positive and CDS'positive cells were moro prevalent. Staining for macrophage with monoclonal clones OX41 and OX42 and al~o with nonspecific esterase IItaining failed to detect them at the graft site. Normal.appearing islets were also present in the graft area from diabelic recipient rals subjected to FKS06 Prol(1Col 1. However, more oggregatcs of CD4-positive and CDB-positive: eclls were prescnt adjacent to the islets than observed in the previous group. Figure 1 shows the scrum glucose levels in six ACI animal, a Wi skin graft performed at day 90 resulted in its return to hyperglycemia in 9 days. In contrast, the two animals that received the rctramplantation of fresh islet allograft under the KC rejected the grafts in 5 and 8 days. Two rats without retransplantation remained hyperglycemic.
The Wi rat islets that functioned long·tcrm IPo In diabetic ACI rats still retained their antigenicity. Wi strain skin graft performed in these animals induced islet graft rejection in three out of three cases between 9 and 13 days. Both Wi and the third-party Le skin grafts were rejected in the fint-sct fasbion in 12 to 13 days.
P.05 Table 2 shows the efficacy ofPKS06 protoooill treatment on islet allograflllurvival in diabelicACI recipients that had rejected it Wi islet graft performcd SO to 177 days previously. The immunosuppression was effective in achieving long· term survival in all eight recipients, with three out of eight recipients lIehieving indefinite graft survival. This was not si,nificantiy different from that achieved in nonsensit!zed animals ( Table 2 group 3 v Table 1 group 6, P == .10).
In contrast, when the interval between the lint and second TR was ofshortcr duration, ie, 2 weeks, FKS06 immunosuppression alone (group 4) and in combination with cyclophOSphamide (group 5) was found to be Ineffective, with only Figure 2 shows that in ACI rats without FKS06 immunosuppression, anti-islet donor Ab titers increased rapidly and peaked at day 14 at 77.3 :!:: 0.9 (n = 12, mean ± SEM). In comparison, tbe and-Wi Ab titers were significantly lower in islet allograft recipients heated with FKS06, with the peak titer at 11.1 ± 2.4 (n -7) on day 7. The anti-Wi Ab was negligible In the recipients at the time of the second TR when the inte1'V81 between the fitst and second TR was more than SO days In sensitized recipients. The peak Ab titers remained low at 8.0 :t 2.2 (n :: S) after the TR while immunosuppressed with FK506. In comparison, 10 the recipients that had recently rejeeted the first Wi islet allograft, anti-Wi Ab titers were high, with a mean of 115 ;I: 12.8 (n = 5). and increased further to S120n day 8 after the second TR despite FKS06 immunosuppression.
DISCUSSION
Results of the present study show that FKS06 was an effective immunosuppressant in prolonging fresh islet allograft survival across the MHC barrier. At a daily dosage of 1 mg{kg administered 1M for 14 days starting on the day of TR, signifiatDt prolongation of fresh Wi islet allograft survival was observed both under the KC and IPo. 111e 
10.
14. Earlier. Yasunami et al s failed to achieve prolonged islet allograft survival under KC. This difference could be due to the lower dosage of FKS06 administered for a shorter period than In the present study. The route ofTR seems to be important. since we observed the superiority of the IPo over the KC site in the islet TR model. This confirmll prcvious observations.' The suggestion that FKS()) is melaboliied extensivoly in the livor before I!xcretion may contribute to the superiority of the IPo site. I I Despite voluminous litcruture on the effect 01 various immunosuppJ'CMivo agents and islet pretreatment prolo-0011 on islet sUlVival in nonscnsitizcd animals, relatively little information is a""ilable for sansitized animals. The data demonstrated that FK506 was effective in prolonging the second Islet allograft survival in sensitized raL'!, provided the antidonor immune activities had subsided.
Our results would indicate that the classic form of tolerance was absent in rats with long-term islet allograft function. as they railed to retain the donor-strain skin graft. Furthermore, the retransplanted islets were susceptible to induction of rejection by dOllOr-straln skin graft, However, some form of tolerance: was present in these animals, since retransplantation of fresh donor-strain islets IPo following the destruction of the islet graft with STZ resulted in prolonged normoglycemia without further FKS06 immunosUpptCSsion. This observation is therefore similar to tbat of Kamei and Yasunami. who observed a similar tolcrancc state induced in their rats with cydosporin A treatmenL 1% Ricordi et al 13 Improvement of the treatment regimen using FK506 should minimize the side effects, and allow it to become useful in clinical i:r;let TR.
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